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A B S T R A C T
Purpose: Unverricht–Lundborg disease (EPM1) is the most common form of progressive myoclonus
epilepsies. The genetic background is a homozygous dodecamer repeat extension mutation in the
cystatin B (CSTB) gene. However, mutations occurring in a compound heterozygous form with the
expansion mutation have also been reported. In Finland, we have found ﬁve EPM1 patients compound
heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene
(chEPM1). There arenoprevious clinical or neurophysiological studies on thesepatients. Thus,weaimed to
characterize possible functional alterations in primary motor cortical areas.
Methods: Five chEPM1 patients were compared with homozygous patients and healthy controls. All
patients underwent a clinical evaluation to characterize the severity of the symptoms. Navigated
transcranial magnetic stimulation (TMS) was used to study cortical excitability by determining the
motor thresholds (MT), silent periods (SP) andmotor evoked potential (MEP) characteristics. Continuous
electroencephalography (EEG) was recorded during the measurements. Voxel-based MRI morphometry
(VBM) was used to study differences in gray matter volume.
Results: The chEPM1 patients exhibited an inhibitory cortical tonus reﬂected as elevated MTs and
prolonged SPs. EEG showed spontaneous focal epileptiform activity in centro-temporal and parietal
areas in addition to more widespread and generalized discharges. VBM revealed loss of gray matter
volume in primary motor cortical areas and thalami.
Discussion: The chEPM1 patients exhibited functional and structural changes in primary motor cortical
areas. The functional changes are more profound as compared to homozygous patients, suggesting a
neurophysiological background for the more severe clinical symptoms.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Unverricht–Lundborg disease (progressive myoclonus epilepsy
type 1, EPM1), is the most common form of progressive myoclonus
epilepsies (PMEs) worldwide with highest prevalence in Scandina-
via and in the Mediterranean region.1–3 The symptoms of EPM1 are
progressive of nature and may lead to severe disability. The initial
symptoms include myoclonic jerks and generalized tonic–clonic
seizures,whichbecomeevidentbetweentheageof6and16years.2,4
The epileptic seizures can be controlled relatively well by adequate* Corresponding author. Tel.: +358 17 174115; fax: +358 17 173244.
E-mail address: danner@hytti.uku.ﬁ (N. Danner).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.010medication. However, gradually intention tremor, ataxia and
dysarthria may develop making the affected individual wheel-
chair-bound and dependent on other people in daily routines.5,6
EPM1 is causedby amutation in the CSTBgene encoding cystatin
B, which produces an unstable extension of a 12-nucleotide
dodecamer repeat.7 The genetic defect is inherited in an autosomal
recessive manner, and thus, all affected individuals should be
homozygous for the mutation.8,9 However, nine other EPM1
associated mutations in the CSTB gene, occurring in a compound
heterozygous form with the expansion mutation, have also been
identiﬁed.10 In Finland, we have found ﬁve EPM1 patients
compound heterozygous for the dodecamer repeat expansion and
the c.202C>T mutation in the CSTB gene. These patients seem to
have an earlier onset of the symptoms and a more severe clinicalvier Ltd. All rights reserved.
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mutations are referred to as compound heterozygotes (chEPM1).
In early studies on EPM1 the diagnosis of the condition was
based almost exclusively on clinical characteristics, and thus, the
genetic background of the patients may have been non-uniform.
Therefore it is essential to re-evaluate the clinical and neurophysi-
ological characteristics in genetically veriﬁed EPM1 patients. In
addition, the existence of possible genotype–phenotype correla-
tions should be explored.
There are no previous clinical or neurophysiological studies on
chEPM1 patients. However, generally myoclonus is regarded to
derive from abnormally increased cortical excitability with a
contribution of impaired cortical inhibition,11–13 which is consis-
tent with ﬁndings in various forms of PMEs, including EPM1.14–17
Typical EEG ﬁndings in EPM1 include normal or moderately slow
background activity and generalized fast spike or polyspike-wave
discharges that can occur either spontaneously or provoked by
exogenous stimuli.6,18,19
Transcranial magnetic stimulation (TMS) is a non-invasive
method applicable for the evaluation of cortical excitability.20 The
stimulation can be targeted precisely and repeatedly using MRI-
navigated TMS.21,22 Typical TMS parameters for studying cortical
excitability include the cortical motor threshold (MT) and the
silent period (SP). The MT decreases in hyper-excitable states and,
respectively, increases due to inhibition.23 The SP is prolonged due
to inhibition and shortened in hyper-excitable states.24
We studied possible functional and structural changes of the
primary motor cortex in all the known chEPM1 patients in Finland.
The results were compared with ﬁndings from homozygous EPM1
patients from our previous study, in which elevated MTs and the
absence of age-related shortening of SP duration were reported as
themainTMScharacteristics.25All the resultswerealsocomparedto
age-matched healthy controls. MRI-navigated TMS was used to
study the excitability of the motor cortex, and voxel-based
morphometry to assess structural changes in the very same cortical
areas. Simultaneous conventional EEGwas used tomonitor possible
changes in spontaneous epileptiform activity. The main aim was to
explore possible differences between these two genotypes, espe-
cially related to their primary motor systems.
2. Patients and methods
2.1. Subjects
This study is a part of a large ongoing 4-year-study, carried out
at Kuopio Epilepsy Center, Kuopio University Hospital, jointly with
Neuroscience Center and Folkha¨lsan Institute of Genetics, Helsinki
University. All the patients were evaluated in the ongoing clinical
and molecular genetics study. The patients had either participated
in our previous studies or were referred to the center during the
study. Five genetically veriﬁed EPM1 patients, compound hetero-Table 1
Demographic and clinical data on each patient.
Patient Gender Height (cm) Age (years) Age at onset (years)
1 Male 170 21 7
2 Female 156 34 10
3 Male 158 23 5
4 Female 161 14 6
5 Male 184 36 7
Compound heterozygote EPM1 (mean SD)
16612 269 72
Homozygous EPM1 (mean SD)
16911 3210 102
UMRS, Uniﬁed Myoclonus Rating Scale; AM, myoclonus with action score; FT, functiona
TPM, Topiramate; PIR, Piracetam.zygous for the dodecamer repeat expansion and the c.202C>T
mutation in the CSTB gene, were enrolled in the study.
Demographic and clinical data on the patients are provided in
Table 1. The data from chEPM1 patients were compared with
healthy control subjects (n = 65) and homozygous patients
(n = 24), which were obtained from pre-existing databases
previously published by the authors.25,26 The study was conducted
in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki). The Ethical Committee of
Kuopio University Hospital approved the study protocol and
informed consent was obtained from all participants.
2.2. Clinical assessment of the EPM1 patients
Medical history of the patients was collected retrospectively
using the health institutions’ medical records and by interviewing
the patients and their relatives. A Uniﬁed Myoclonus Rating Scale
(UMRS) test panel was performed as a part of clinical patient
evaluation. The testing was video-recorded and evaluated using a
standard protocol.27 In this study the myoclonus with action score
(AM,max. score 160) and functional test (FT, max. score 28) (UMRS
Sections 4 and 5, respectively) were used to assess the severity of
myoclonus of the patients. Higher UMRS scores indicate more
severe myoclonus.
2.3. Navigated TMS measurement setup and protocol
TMS was performed using an eXimia stimulator and a biphasic
ﬁgure-of-eight coil (Nexstim Ltd., Helsinki, Finland). Navigated
TMSwas utilized to target the stimulations at desired locations and
to keep the coil positioning stable throughout the measurement
(eXimia NBS system, version 2.2.0; Nexstim Ltd., Helsinki, Finland).
Individual 3D T1-weighted MR images (1.5T Siemens Magnetom
Avanto; Erlangen, Germany) were used for navigation. MEPs were
recorded from the thenar muscle (abductor pollicis brevis, APB) by
continuous and stimulus-locked EMG (ME 6000, Mega Electronics
Ltd., Kuopio, Finland). EEG recording was performed using a TMS-
compatible eXimia EEG system (Nexstim Ltd., Helsinki, Finland).
All procedureswere performed identically on both hemispheres.
The MT of the APB was determined at the optimal cortical
representation area using a similar protocol as previously
described.26,28 Thereafter 10 pulses were applied to the optimal
location at an intensity of 120% of the MT to determine the mean
amplitude and latency of the MEP responses. The electric ﬁelds
inducedbystimulatingat theMT intensitywerecomputedusing the
NBSsoftware. Thisallowedtheevaluationofcortical excitabilityalso
by comparing the inducedmaximumelectric ﬁeld strengths (EFs).22
Maximumvoluntarymuscle contraction (MVC) for each subjectwas
determined using bimanual force grips (NewTest, Oulu, Finland).
40%of theMVCwasused forSPmeasurements. SPsweredetermined
by averaging 5 consecutive trials, induced with 120% of the MTUMRS: AM UMRS: FT Treatment (mg/day)
50 5 VPA 1100; LTG 200; LEV 2000
69 9 VPA 900; CZP 2.25; TPM 125; PIR 2400
56 8 VPA 2100; LTG 200; LEV 2250; PIR 31200
40 8 VPA 1400; CZP 6
122 22 VPA 1200; CZP 4; LEV 1500; PIR 3600
6732 107
4126 96
l tests; VPA, Valproic acid; LTG, Lamotrigine; LEV, Levetiracetam; CZP, Clonazepam;
N. Danner et al. / Seizure 20 (2011) 65–71 67intensity.28,29 Due to clinically common impairment in muscle
control in EPM1 patients, MVC could not be determined for all
subjects. In such cases patients were given ﬂexible objects to
squeeze in their hands in order to induce contraction of the thenar
muscles, since thedurationof the SPhasbeen found tobeunaffected
by muscle force.28,30–34
2.4. EEG recording
Continuous scalp EEG was recorded with a 64-channel TMS-
compatible ampliﬁer.35 An electrode capwas tightly attached to the
subject’s head.All electrodeswere referred to anelectrode placed on
the right mastoid. The data was recorded with a 1450-Hz sampling
frequency and 16-bit precision. A trigger signal marking each TMS
pulse was recordedwith the EEG. Vertical electro-oculogram (EOG)
was recorded above and below the left eye. Throughout the
measurement sessionon-lineEEGwasmonitoredbyanexperienced
clinical neurophysiologist to detect possible alterations in cortical
excitability. The recorded EEG was stored for further off-line
analysis.
2.5. MRI voxel-based morphometry (VBM)
The MR images were processed using optimized voxel-based
morphometry (VBM),36 with the VBM2-toolbox (http://dbm.neur-
o.uni-jena/vbm/) in SPM2 (Wellcome Department of Imaging
Neuroscience, London, UK; www.ﬁl.ion.ac.uk/spm) running under
Matlab 6.5 (Mathworks, Inc.). Based on the areas of gray matter
volume, a VBM analysis was performed comparing the chEPM1
patientswithhomozygouspatients andhealthy controls.37 The level
of signiﬁcance was p< 0.05, corrected with the false discovery rate
method for multiple comparisons.
2.6. Data analysis
The MTs were analysed as percentage of maximum stimulator
output as well as induced EFs. The EMG recordings from individual
subjects were analysed using MegaWin software (Mega Electronics
Ltd., Kuopio, Finland). To enable a comparison with the normative
values of healthy control subjects, a correction method was used to
estimate and reduce the effect of the electrode cap on the MT, as it
increases the coil–cortex distance, and thus elevates the MT.38 TheTable 2
TMS results of the compound heterozygous EPM1 patients compared with homozygou
Patient MT (%) EF (V/m)
Original Corrected Standard Adjusted
Left hemisphere
1 ~ – – –
2 61 55 51 72
3 ~ – – –
4 63 57 82 100
5 85 79* 115 125
Right hemisphere
1 ~ – – –
2 66 60 67 84
3 ~ – – –
4 60 54 69 89
5 73 67* 73 93
Healthy controls, n=65 (mean SD)
– 459 – 10220
Homozygous EPM1, n=24 (mean SD)
6813 – 93.026.0 –
Motor thresholds (MT) are shown as both, measured original value and corrected value
strengths (EF) are shown at both, standard depth of 25mmand at the anatomically deﬁne
~In patients 1 and 3 the maximum stimulator output (99%) was insufﬁcient for MT d
p<0.05 as compared to homozygous form of EPM1.
* p<0.05 as compared to healthy population.EFs were determined at a uniform depth of 25 mm from the scalp
and thus take into account the variation in the coil-to-scalpdistance.
Therefore, the EFs are comparable between the patients and the
control subjects regardless of whether an electrode cap was used or
not. The measured MEP latencies were corrected with subject’s
height and age.26 Due to the limited number of chEPM1 patients the
TMS resultswere not analysed on group-level. Thus, the TMS results
of the chEPM1 patients were compared to the healthy controls, as
well as to homozygous EPM1 patients by calculating a two-tailed Z-
score for each parameter separately for all studied subjects. Z-scores
of less than 1.96 or more than 1.96 were regarded as signiﬁcant
(p < 0.05). Normal distribution of both control populations was
veriﬁed using the Kolmogorov–Smirnov test.
3. Results
The age of onset of the disease was lower in chEPM1 patients as
compared to the homozygous EPM1 group (7  2 years vs. 10  2
years, respectively). The chEPM1 patients also tended to have higher
scores in the UMRS AM and FT scales (Table 1). However, due to the
small number of patients, a group-comparison analysis could not be
performed reliably.
The TMS results revealed altered cortical excitability in chEPM1
patients (Table 2). In two patients, measurable MEPs could not be
elicited even at maximal stimulator output intensity, and thus,
theirMTs could not be determined. Since theMT is required for the
determination of further TMS parameters, these parameters could
not be determined either for these two patients with indetermin-
able MTs. On the left hemisphere of patient 5 the MEP and SP
characterization could not be performed at 120% of the MT
intensity due to the high initial MT value (85%). Thus, further
stimulations were performed at 99% of stimulator output intensity
corresponding approximately 116% of the MT.
The EEG was abnormal in all of the studied chEPM1 patients
(Table 3). They exhibitedmild-to-moderate slowing of background
activity in addition to both focal and generalized epileptiform
activity (Fig. 1). Focal epileptiform activity could be observed in all
patients on both hemispheres in frontal and central head regions,
and at times also in more lateral temporal regions in four patients.
Interictal focal spikes and sharp waves appeared separately or in
series lasting up to 3 s, or as a focal electrographic seizures lasting
up to 10 s. There was, however, no clinical correlation for the focals patients and healthy controls.
MEP latency (ms) MEP amplitude (mV) SP duration (ms)
– – –
24.8* 1240 132.1*
– – –
23.8* 696 79.4
29.5* 1082 195.8*
– – –
24.4* 1074 115.4
– – –
23.6 627 66.2
28.8* 1688 143.3*
22.91.5 979720 85.022.7
23.31.9 16721148 93.026.0
for the effect of the EEG cap for comparison with the healthy controls. Electric ﬁeld
d border of cortical white and graymatter for comparisonwith the healthy controls.
etermination, and thus, further parameters could not be determined.
Table 3
EEG ﬁndings of the compound heterozygous EPM1 patients during the TMS session.
Patient Background activity Epileptiform activity
Focal Generalized
1 Mild slowing FC dex/sin PSW <2s
2 Marginal slowing (occipital alpha 8Hz) FCT dex/sin PSW <2s
3 Mild to moderate slowing FCT dex/sin, very frequently PSW <1s
4 Moderate slowing FCT dex/sin Spike trains dex PSW-SW discharge 13 s
5 Mild to moderate slowing FCT dex/sin, Sin >10 s Not present
Dex, Right hemisphere; Sin, Left hemisphere; PSW, Polyspike-wave; SW, Slow wave; F, Frontal; C, Central, T; Temporal.
[()TD$FIG]
Fig. 1.An illustrative example of both generalized (A) and focal (B) epileptiformEEG activity in a compoundheterozygous EPM1patient. The dashed linesmark intervals of 1 s.
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ictal nature. In addition to focal abnormalities, generalized
polyspike-wave discharges were also observed in four patients.
TMS did not produce any aggravation of clinical myoclonus, nor
were there any EEG features of enhanced excitation.
The VBM analysis revealed gray matter volume loss in bilateral
cortical motor areas and thalami (Fig. 2) in chEPM1 patients as
compared to healthy controls. However, there were no evident
group-level differences in comparison with homozygous patients.
[()TD$FIG]
Fig. 2. Areas of gray matter volume loss identiﬁed by voxel-based morphometry4. Discussion
Unverricht–Lundborg disease (EPM1) patients compound
heterozygous for the dodecamer repeat expansion and the
c.202C>Tmutation in the CSTB gene exhibitedmarked functional
changes in cortical excitability and reduced graymatter volume in
primary corticalmotor areas. Their EEGs revealed also evidence of
focal epileptiform activity in the same cortical regions. We
believe that these observations are relevant to the underlyingin compound heterozygous EPM1 patients as compared to healthy controls.
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myoclonus.
The generation of myoclonus is associatedwith an imbalance of
excitatory and inhibitory neuronal circuits, which may be
generated in any part of the central nervous system.12,15,39,40 In
EPM1, it is regarded as epileptic, i.e., of cortical origin.41 However,
in addition to pure cortical myoclonus, the myoclonus in EPM1
may also be generated by a mechanism requiring a somatosensory
trigger, with both, a cortical and a subcortical contribution.11,42
There are no previous TMS studies on cortical excitability in
chEPM1 patients, but in studies on various forms of PMEs the
generation of myoclonus is regarded to derive from hyperexcitable
responses to sensory stimuli, which trigger the motor responses
due to a lack of cortical inhibition. Furthermore, aberrant neuronal
loops have been proposed as a possible mechanism.14–17 However,
in addition to cortical hyperexcitability, few studies also reported
evidence of increased inhibition, reﬂected as elevated MTs. This
was supported by ﬁndings from a large-scale study on genetically
veriﬁed homozygous EPM1 patients.16,17,25 The major drawbacks
ofmost previous studies are the heterogeneity and limited number
of subjects, as different forms of PMEs have been reported to
exhibit some peculiar characteristics of cortical excitability.14,43
Thus, the discrepancies between the results from studies lacking a
genetic veriﬁcation of the disease form should be interpreted with
caution and suggest a need for re-evaluation.
Thecurrentﬁndings inchEPM1patients coherewith theprevious
ﬁndings in genetically veriﬁed EPM1, since all of our patients
exhibited abnormal characteristics of cortical excitability reﬂected
as elevated MTs in comparison with healthy controls (Table 2). Our
results suggest also that these alterations may bemore profound in
chEPM1 patients as compared to homozygous patients. However,
due to the indeterminably high MTs in two patients along with the
small number of subjects this assumption lacks statistical evidence.
ElevatedMT is associatedwith either reduced cortical excitability or
increased inhibition, and thus, is a rather paradoxical ﬁnding in
patients with epileptic myoclonus. In previous studies elevated MT
has therefore been attributed to the use of anti-epileptic drugs
(AEDs).15,16 The difference of the MT in comparison to healthy
controlsmayresult fromAEDsat least toacertainextent, sincemany
of themhave been reported to increase theMT.44–51 In EPM1 similar
medication is used with individually adjusted maximum tolerated
dosages regardless of the precise genetic background, and thus,
differences between these groups unlikely derive completely from
differences in AED use. Additionally, no correlation between dosage
andMThas been established formost AEDs, especiallywhenused in
different combinations as in EPM1. Furthermore, normal MTs have
also been reported in patients treated with AEDs.17 Therefore we
hypothesize that the higher MTs in chEPM1 may be partially
explained by a more severe disease form, reﬂecting a possible
reactive mechanism to increased excitability.
The studied chEPM1 patients exhibited prolongation in MEP
latencies in comparison with healthy controls (Table 2). In one
subject the difference was signiﬁcant also in comparison with
homozygous patients. Prolongation of MEP latencies has been
reported also in homozygous patients in some previous stud-
ies.14,15,17 MEP latencies may, however, be affected by various
pathological processes of the central and peripheral nervous
system in addition to co-existing other clinical conditions. In our
study population, the large age variation and the use of AEDs may
act as confounding factors in the MEP analysis. Thus, further
studies are required to determine, whether this ﬁnding can be
attributed to the actual disease process.
The SPs were prolonged in chEPM1 patients as compared to
healthy subjects, and showed a tendency towards prolongation
even in comparison with homozygous EPM1 patients (Table 2).
Previously prolonged SP durations have been reported as a peculiarﬁnding in homozygous EPM1 patients.25 In epilepsies caused by a
focal cortical lesion, the SPs have been reported to be shortened in
the epileptogenic hemisphere and to be prolonged on the
contralateral side. Thus, the prolongation of the SP is regarded
as a reactive phenomenon to balance out the hyper-excitability
induced by the epileptogenetic focus.42 In chEPM1 patients, the
prolonged SPs may therefore be interpreted to reﬂect a reactive
inhibitory mechanism to the underlying hyperexcitable process.
The effect of AEDs on SP-duration remains debatable, since
previous data is highly inconsistent. Normal, shortened and
prolonged SPs have been attributed to the AEDs used by our
study subjects,44–47,50,51,53 and thus, the observed uniform
prolongation of the SPs is unlikely explained by mere AED effects.
VBM revealed signiﬁcant gray matter volume loss bilaterally in
the primary motor areas and thalami supporting the role of the
primary motor areas in the pathophysiology of chEPM1 (Fig. 2).
The volume loss in the thalami coheres with previously reported
thalamostriatal dopaminergic defects in EPM152 suggesting a
possible contributing pathophysiological thalamocortical mecha-
nism. There were no signiﬁcant differences in the VMB results
between chEPM1 patients and homozygous patients, possibly due
to the limited number of chEPM1 subjects not allowing the
detection of subtle group-level differences. However, itmay also be
that the difference between the genotypes is only functional, and
thus, remains undetectable by anatomical imaging methods.
All studied chEPM1 subjects exhibited spontaneously abnormal
EEG characteristics (Table 3). The background activitywas slowed in
all subjects, and furthermore, both focal and generalized epilepti-
form activity was observed (Fig. 1). In homozygous EPM1 patients,
normal ormoderate slowing of background activity and generalized
fast spike or polyspike-wave (PSW) discharges have been reported
as common EEG ﬁndings. There is also evidence of electrophysio-
logical and clinical stimulus-sensitivity.6,18,19,54 Even though focal
EEG abnormalities have been described in some forms of PME,55 it is
not a typical ﬁnding in EPM1. However, in all the studied chEPM1
patients, focal EEG activity could be observed on both hemispheres
in frontal and central regions, and at times also in more lateral
temporal regions in four patients. Thus, the EEG in chEPM1 more
commonly contains focal epileptiform activity in comparison to
previously reportedﬁndings inhomozygousEPM1.Theepileptiform
EEG features in homozygous EPM1 have been also reported to
gradually decline over time along with clinical reduction of seizure
frequency.56,57 Due to the relatively young age of our patients, it
cannot be stated, whether the EEG abnormalities in chEPM1 are
more persistent over time correlating with a more severe clinical
picture.We, however, did not observe a similar conclusive decline of
epileptiformactivity even in patientswith a disease duration of over
20 years.
The studied chEPM1 patients present unique characteristics in
both TMS parameters and EEG recordings that are more
pronounced than in EPM1. The ﬁndings imply a disturbed balance
between excitatory and inhibitory neuronal functions within
primarymotor cortical areas, which is supported by the VBMdata,
as the structural gray matter volume loss is also detectable at
primarymotor areas. The disturbed function of the primarymotor
cortex ismanifested also in the clinical evaluation, where chEPM1
patients presented more profound action myoclonus reﬂected as
higher UMRS scores. Since the basic pathophysiology of myoclo-
nus is attributed to enhanced neuronal excitability we conclude
that the inhibitory tonus observed in chEPM1 is a reactive
mechanism to the disease process, especially to the devastating
myoclonus. The distinct pathophysiology of the compound
heterozygous formof EPM1with the dodecamer repeat expansion
and the c.202C>Tmutation in the CSTB genemay result in a more
severe form of the disease, and thus, also the reactive inhibitory
phenomena are more evident.
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